News & Press
GeNeuro Reports 2020 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2020 at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2020 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2020-Results-ENG.pdf
GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) Present Temelimab Neurodegeneration Prevention Study at MSVirtual2020
Geneva, Switzerland, September 14, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a presentation by Professor Fredrik Piehl of the Karolinska Institutet’s Academic Specialist Center (ASC) at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting) provided the rationale and outline on the Phase 2 ProTEct-MS clinical study of temelimab initiated earlier this year.
https://geneuro.ch/data/news/GeNeuro-PR-Presentation-at-8th-ACTRIMS-ECTRIMS-2020-EN-vf.pdf
GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) to Present ProTEct-MS Study of Temelimab at MSVirtual2020
Geneva, Switzerland, September 8, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the company and the Karolinska Institutet’s Academic Specialist Center (ASC) will present the rationale of its new Phase 2 study at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting), held September 11-13, 2020. The trial, which is evaluating the administration of temelimab in patients with relapsing MS to address disease progression independent of relapses following treatment with rituximab, is being conducted at the Karolinska Institutet’s Academic Specialist Center, Stockholm, Sweden.
https://geneuro.ch/data/news/GeNeuro-PR-8th-ACTRIMS-ECTRIMS-2020-eng.pdf
GeNeuro: financial information and business update for the second quarter 2020
Geneva, Switzerland, July 23, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 second quarter cash position and issued a business update.
https://geneuro.ch/data/news/2020.07.23-GeNeuro-PR-Q2-2020-EN-Final.pdf
GeNeuro announces the publication in Science Advances of data establishing clear link between human endogenous retroviral proteins and psychotic disorders
Geneva, Switzerland, 21 July 2020 – 08:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced data showing the etiological interplay between human endogenous retroviral (HERV) proteins and the emergence of psychotic phenomena in mice.
https://geneuro.ch/data/news/2020.07.21-GeNeuro-PR-Fondamental-EN-final.pdf
GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, June 25, 2020 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), today announces the inclusion of the first patient in its Phase 2 trial of temelimab in MS at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, Sweden.
https://geneuro.ch/data/news/2020.06.25-GeNeuro-MSResumption-EN-VF.pdf
GeNeuro Announces the Approval of all Resolutions proposed at the AGM
Geneva, Switzerland, May 28, 2020 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2020.
https://geneuro.ch/data/news/2020.05.28-GeNeuro-AGM-28052020-ENG.pdf
GeNeuro: financial information and business update for the first quarter 2020
Geneva, Switzerland, April 27, 2020 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2020 first quarter cash position and issued a business update.
GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer
Geneva, Switzerland, April 21, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis , today announces the appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.
https://geneuro.ch/data/news/GeNeuro-PR-CMO-appointment-EN.pdf
GeNeuro Reports 2019 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 7, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today reported its full-year results for the year ended December 31, 2019 and provided a corporate update
GeNeuro Phase 2 multiple sclerosis trial update
Geneva, Switzerland, March 19, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced the temporary postponement of its planned Phase 2 trial of temelimab in multiple sclerosis (MS) at the Karolinska Institutet’s Academic Specialist Center (ASC), Stockholm, Sweden, to prioritize healthcare resources behind the fight of COVID-19 and to reduce the risk for MS patients.
https://geneuro.ch/data/news/GeNeuro-PR-TemelimabCOVID19-EN.pdf
GeNeuro: successful €17.5 million private placement
Geneva, Switzerland, January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the “Company”), today announced the successful completion of a €17.5 million international private placement only to certain qualified and institutional investors.
https://geneuro.ch/data/news/2020-01-31-GeNeuro-Closes-Financing.pdf